Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

March 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • An account of how far we have come to treating neuroblastoma

Metastatic melanoma: Dual treatment to fight

Trimodal brain imaging may accurately detect human brain activities

An account of how far we have come to treating neuroblastoma
  • BiotechToday
  • World

An account of how far we have come to treating neuroblastoma

BioTech Today July 15, 2021July 14, 2021

Vaishnavi Kardale, Bioinformatics Centre, Savitribai Phule Pune University

Our cells divide for growth. Cancer starts when the growth of the cells gets out of control. Any cell can become cancerous at any stage and any age. Cancer development can begin even in fetal cells.

What is Neuroblastoma?

Neuroblastoma (NB) is a type of cancer that starts in a very early form of nerve cells that are commonly found in embryos or fetuses. Neuro refers to nerves and blastoma refers to cancer that occurs in premature cells. This cancer occurs most commonly in infants and young children. Neuroblastoma occurs in the nerve cells of the sympathetic nervous system. In our body, all the functions are controlled by the nervous system. Some functions are voluntary while some are involuntary. Involuntary functions are the ones that are not in our control like breathing, digestion, heart rate, and other functions. These functions are included in the autonomic nervous system. The sympathetic nervous system is a part of the autonomic nervous system.

Neuroblastoma begins in the abdomen and is commonly found on adrenal glands on top of the kidneys. NB accounts for 15% of all pediatric cancer. The survival of high-risk neuroblastoma is less than 50%. Approximately half of the high-risk patients do not respond to the current prescribed therapy protocol or relapse in the first two years of the treatment. In addition to these many patients develop multiple drug resistance and severe drug toxicities. NB is complex and exhibits heterogeneity in biological, morphological, clinical, and genetic features making it difficult to develop therapies against it. This has made NB a topic of interest for a lot of researchers.

How far has research come?

Genomic analysis suggests that chromosome instability (mis-segregation of the chromosome during cell division) might be responsible for the development of NB. It is crucial to understand the defects in spindle formation and centromere separation that are leading to chromosome instability. One of the observations by researchers is that high-risk NB patients had a hemizygous deletion of chromosome 11q 22-23. This is peculiar as genes on chromosome 11 have a role in DNA repair and its loss may be associated with the progression of NB.

Amongst all therapy options immunotherapy has emerged as the most effective one yet as it causes less toxicity among patients than other patients. With rapid modifications to the treatment, it is expected that the side effects are going to reduce.

Very few compounds that target epigenetic factors are under clinical trial at the moment. More research needs to be done on them. New approaches should also be developed while improvising the older ones. One of the new approaches in the development of HIFU (High-Intensity Focused Ultrasound). MR (Magnetic Resonance)-HIFU is being developed for the treatment of NB. It is being implemented in relapsed NB patients. Phase I trials are currently in progress at Children’s National Research Institute in Washington DC. Combining MR-HIFU with existing chemotherapy needs to be implemented to augment chemo-response of NB, increase local control, and decrease toxicity.

What next?

Currently, research is being done using mice, zebrafish, and chick chorioallantoic membrane (CAM). Using more physiologically relevant models could have a high impact on research as it can mimic the genetic complexity of the tumour. A patient-derived xenograft model or 3D tissue-engineered system is recommended to better understand the pathogenesis of NB.

Overall, it is crucial to understand the genetic complexity of NB and the molecular pathways it follows for the progression and onset of cancer. The findings in this area should be exploited to develop new targets for therapy. The purpose of developing new treatments should be to cure children with NB with minimal toxicity and side effects.

Also read: Understanding Cancer pathophysiology via isotopic tracing

Reference:

  1. Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021). Molecular targeting therapies for neuroblastoma: Progress and challenges. Medicinal Research Reviews, 41(2), 961–1021. https://doi.org/10.1002/med.21750

Author info:

Vaishnavi Kardale is a master’s student at the Bioinformatics Centre, Savitribai Phule University. She is interested in protein folding mechanisms and wants to study them further.

  1. https://bioxone.in/news/worldnews/the-gene-responsible-for-eye-lens-formation-revealed/
  2. https://bioxone.in/news/worldnews/comeback-of-tuberculosis-but-its-drug-resistant-now/
  3. https://bioxone.in/news/worldnews/a-drug-to-reduce-covid-infection-by-99/
  4. https://bioxone.in/news/worldnews/the-effect-of-stroke-on-muscle-sarcomere/
  5. https://bioxone.in/news/worldnews/artificial-intelligence-ai-for-efficient-covid-testing/
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged cancer chemotherapy Child cancer HIFU Immunotherapy infants molecular therapy neuroblastoma

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Trimodal brain imaging may accurately detect human brain activities

BioTech Today July 15, 2021

Parnad Basu, Amity University Kolkata The brain is the most complex part of the human body and controls what we do or feel, our reflexes, emotions, everything. However, we don’t know our brains fully. Scientists are continuously trying to decode how the human brain functions, pinpointing where, when, and how things happen in the brain. […]

Trimodal brain imaging

Related Post

  • World

GENOMIC ANALYSIS OF SALIVARY DUCT CARCINOMA

bioxone September 18, 2020September 18, 2020

–Subhangi Das , Bankura Sammilani College Salivary duct carcinoma (SDC) is one of the rarest incursive subtypes of salivary gland cancer that microscopically resembles high-grade ductal carcinoma of the breast, with both in situ and invasive pattern. Ordinary chemotherapy and radiation have just restricted viability for the metastatic SDC2, thus treatment is needed against this […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Analysis of clinical characteristics of Takayasu’s arteritis patients

BioTech Today July 24, 2021July 23, 2021

Shrestha Dutta, Amity University Kolkata About Takayasu’s arteritis (TA): Takayasu’s arteritis (TA) is a chronic vasculitis of obscure etiology, predominantly influencing the aorta and its essential branches in ladies aged from 20 to 40 years. The assessed occurrence of TA in Europe and the USA is 0.4–2.6 per million individuals, while the pervasiveness is estimated […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Splicing factor SF3B1 promotes endometrial carcinoma progression?

bioxone October 12, 2020October 11, 2020

Arjama Roy, Amity University Kolkata Endometrial cancer is the foremost common type of cancer that affects the feminine reproductive tract. It grows rapidly and tends to spread to other parts of the body. Earlier, the causative agent of endometrial carcinoma wasn’t known aside from the transcriptional effects of steroid hormones. As a result of which limited therapeutic options were provided to the diagnosed women. Recent work […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy